Skip to main content
Top
Published in: Sleep and Breathing 1/2013

01-03-2013 | Original Article

Might psoriasis be a risk factor for obstructive sleep apnea syndrome?

Authors: Semsettin Karaca, Fatma Fidan, Faruk Erkan, Serkan Nural, Tulay Pinarcı, Ersin Gunay, Mehmet Unlu

Published in: Sleep and Breathing | Issue 1/2013

Login to get access

Abstract

Background

It is believed that psoriasis is a chronic systemic inflammatory disease. Obstructive sleep apnea syndrome (OSAS) is a disease influencing all systems and characterized by intermittent partial or complete obstruction of the upper respiratory tract during sleep. In our study, we aimed to investigate the frequency of OSAS in patients previously diagnosed with psoriasis in order to investigate a potential association between chronic inflammation psoriasis and OSAS.

Methods

Thirty-three patients diagnosed with psoriasis by biopsy were enrolled into the study. Demographics of patients, Psoriasis Area Severity Index (PASI), Dermatology Life Quality Index (DLQI), and Epworth Sleepiness Scale were examined. All patients underwent polysomnography.

Results

OSAS was determined in 18 of 33 patients with psoriasis (54.5 %). Eleven of the 18 patients had mild, 2 had moderate, and 5 had severe OSAS. Mean age was significantly higher in the OSAS group in comparison with non-OSAS group (54.4 ± 15.5 vs 39.4 ± 11.8, respectively, p < 0.05). Mean PASI was higher in the OSAS group in comparison with that of non-OSAS group, and the difference was not significant, although mean DLQI was lower (p > 0.05). It is believed that this was caused by the small patient population.

Conclusion

We detected that the frequency of OSAS in patients with psoriasis was much higher than that in the normal population. Though OSAS is not easy to diagnose without detailed testing, it should be investigated in psoriatic patients with long disease duration and high PASI score, and patients refractory to conventional systemic treatment. Physicians treating patients with psoriatic disease should incorporate this life-altering comorbidity into their assessment of disease and selection of treatment.
Literature
1.
go back to reference Henseler T, Christophers E (1995) Disease concomitance in psoriasis. J Am Acad Dermatol 32:982–986PubMedCrossRef Henseler T, Christophers E (1995) Disease concomitance in psoriasis. J Am Acad Dermatol 32:982–986PubMedCrossRef
2.
go back to reference Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58:826–850PubMedCrossRef Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58:826–850PubMedCrossRef
3.
4.
go back to reference Tishler PV, Larkin EK, Schluchter MD, Redline S (2003) Incidence of sleep disordered breathing in an urban adult population: the relative importance of risk factors in the development of sleep-disordered breathing. JAMA 289:2230–2237PubMedCrossRef Tishler PV, Larkin EK, Schluchter MD, Redline S (2003) Incidence of sleep disordered breathing in an urban adult population: the relative importance of risk factors in the development of sleep-disordered breathing. JAMA 289:2230–2237PubMedCrossRef
5.
go back to reference Young T, Peppard PE, Gottlieb DJ (2002) Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 165:1217–1239PubMedCrossRef Young T, Peppard PE, Gottlieb DJ (2002) Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 165:1217–1239PubMedCrossRef
6.
7.
go back to reference Fidan H, Fidan F, Unlu M, Ela Y, Ibis A, Tetik L (2006) Prevalence of sleep apnoea in patients undergoing operation. Sleep Breath 10:161–165PubMedCrossRef Fidan H, Fidan F, Unlu M, Ela Y, Ibis A, Tetik L (2006) Prevalence of sleep apnoea in patients undergoing operation. Sleep Breath 10:161–165PubMedCrossRef
8.
go back to reference Shepard JW (1992) Hypertension, cardiac arrhythmias, myocardial infarction, and stroke in relation to obstructive sleep apnea. Clin Chest Med 13:437–458PubMed Shepard JW (1992) Hypertension, cardiac arrhythmias, myocardial infarction, and stroke in relation to obstructive sleep apnea. Clin Chest Med 13:437–458PubMed
9.
go back to reference Buslau M, Benotmane K (1998) Cardiovascular complications of psoriasis: does obstructive sleep apnoea play a role? Acta Dermatol Venerol 79:234 Buslau M, Benotmane K (1998) Cardiovascular complications of psoriasis: does obstructive sleep apnoea play a role? Acta Dermatol Venerol 79:234
10.
go back to reference Patel RV, Shelling ML, Prodanovich S, Federman DG, Kirsner RS (2011) Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature. J Gen Intern Med 26(9):1036–1049PubMedCrossRef Patel RV, Shelling ML, Prodanovich S, Federman DG, Kirsner RS (2011) Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature. J Gen Intern Med 26(9):1036–1049PubMedCrossRef
11.
go back to reference Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M (2010) Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci 7(5):284–289PubMedCrossRef Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M (2010) Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci 7(5):284–289PubMedCrossRef
12.
go back to reference Ozturkcan S, Ermertcan AT, Eser E, Sahin MT (2006) Cross validation of the Turkish version of ermatology life quality index. Int J Dermatol 45(11):1300–1307PubMedCrossRef Ozturkcan S, Ermertcan AT, Eser E, Sahin MT (2006) Cross validation of the Turkish version of ermatology life quality index. Int J Dermatol 45(11):1300–1307PubMedCrossRef
13.
go back to reference Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540–545PubMed Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540–545PubMed
14.
go back to reference Rechtschaffen A, Kales A (1968) A manual of standardized terminology, techniques, and scoring system for sleep stages in human subjects. Brain Information Service, UCLA, Los Angeles Rechtschaffen A, Kales A (1968) A manual of standardized terminology, techniques, and scoring system for sleep stages in human subjects. Brain Information Service, UCLA, Los Angeles
15.
go back to reference Iber C, Ancoli-Israel S, Chesson A, Quan S, For the American Academy of Sleep Medicine (2007) The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications, 1st edn. American Academy of Sleep Medicine, Westchester Iber C, Ancoli-Israel S, Chesson A, Quan S, For the American Academy of Sleep Medicine (2007) The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications, 1st edn. American Academy of Sleep Medicine, Westchester
16.
go back to reference Lavie P, Herer P, Hoffstein V (2000) Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. Br Med J 320:479–482CrossRef Lavie P, Herer P, Hoffstein V (2000) Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. Br Med J 320:479–482CrossRef
17.
go back to reference Guasti L, Marino F, Cosentino M, Maroni L, Maresca AM, Colombo F, Maio RC, Castiglioni L, Saporiti F, Loraschi A, Gaudio G, Bernasconi A, Laurita E, Grandi AM, Venco A (2011) Cytokine production from peripheral blood mononuclear cells and polymorphonuclear leukocytes in patients studied for suspected obstructive sleep apnea. Sleep Breath 15:3–11PubMedCrossRef Guasti L, Marino F, Cosentino M, Maroni L, Maresca AM, Colombo F, Maio RC, Castiglioni L, Saporiti F, Loraschi A, Gaudio G, Bernasconi A, Laurita E, Grandi AM, Venco A (2011) Cytokine production from peripheral blood mononuclear cells and polymorphonuclear leukocytes in patients studied for suspected obstructive sleep apnea. Sleep Breath 15:3–11PubMedCrossRef
18.
go back to reference Wu Y, Mills D, Bala M (2008) Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol 7:373–377PubMed Wu Y, Mills D, Bala M (2008) Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol 7:373–377PubMed
19.
go back to reference Azfar RS, Gelfand JM (2008) Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 20:416–422PubMedCrossRef Azfar RS, Gelfand JM (2008) Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 20:416–422PubMedCrossRef
21.
go back to reference Gowda S, Goldblum OM, McCall WV, Feldman SR (2010) Factors affecting sleep quality in patients with psoriasis. J Am Acad Dermatol 63(1):114–123PubMedCrossRef Gowda S, Goldblum OM, McCall WV, Feldman SR (2010) Factors affecting sleep quality in patients with psoriasis. J Am Acad Dermatol 63(1):114–123PubMedCrossRef
22.
go back to reference Rhew EY, Ramsey-Goldman R (2006) Premature atherosclerotic disease in systemic lupus erythematosus, role of inflammatory mechanisms. Autoimmun Rev 5:101–105PubMedCrossRef Rhew EY, Ramsey-Goldman R (2006) Premature atherosclerotic disease in systemic lupus erythematosus, role of inflammatory mechanisms. Autoimmun Rev 5:101–105PubMedCrossRef
23.
go back to reference Dessein PH, Stanwix AE, Joffe BI (2002) Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 4:R5PubMedCrossRef Dessein PH, Stanwix AE, Joffe BI (2002) Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 4:R5PubMedCrossRef
24.
go back to reference Asanuma Y, Chung CP, Oeser A, Shintani A, Stanley E, Raggi P, Stein CM (2006) Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 33:539–545PubMed Asanuma Y, Chung CP, Oeser A, Shintani A, Stanley E, Raggi P, Stein CM (2006) Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 33:539–545PubMed
25.
go back to reference Callis Duffin K, Wong B, Horn EJ, Krueger GG (2009) Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. J Am Acad Dermatol 60(4):604–879PubMedCrossRef Callis Duffin K, Wong B, Horn EJ, Krueger GG (2009) Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. J Am Acad Dermatol 60(4):604–879PubMedCrossRef
26.
go back to reference Choi JK, Kim MY, Kim JK, Park JK, Oh SS, Koh SB, Eom A (2011) Association between short sleep duration and high ıncidence of metabolic syndrome in midlife women. Tohoku J Exp Med 225(3):187–193PubMedCrossRef Choi JK, Kim MY, Kim JK, Park JK, Oh SS, Koh SB, Eom A (2011) Association between short sleep duration and high ıncidence of metabolic syndrome in midlife women. Tohoku J Exp Med 225(3):187–193PubMedCrossRef
27.
go back to reference Gupta AK, Goldfarb MT, Ellis CN, Voorhees JJ (1989) Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 20:1088–1093PubMedCrossRef Gupta AK, Goldfarb MT, Ellis CN, Voorhees JJ (1989) Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 20:1088–1093PubMedCrossRef
28.
29.
go back to reference Van den Borne BE, Landewé RB, Houkes I, Schild F, van der Heyden PC, Hazes JM, Vandenbroucke JP, Zwinderman AH, Goei The HS, Breedveld FC, Bernelot Moens HJ, Kluin PM, Dijkmans BA (1998) No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum 41:1930–1937PubMedCrossRef Van den Borne BE, Landewé RB, Houkes I, Schild F, van der Heyden PC, Hazes JM, Vandenbroucke JP, Zwinderman AH, Goei The HS, Breedveld FC, Bernelot Moens HJ, Kluin PM, Dijkmans BA (1998) No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum 41:1930–1937PubMedCrossRef
30.
go back to reference Stern RS, Fitzgerald E, Ellis CN, Lowe N, Goldfarb MT, Baughman RD (1995) The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. J Am Acad Dermatol 33:44–52PubMedCrossRef Stern RS, Fitzgerald E, Ellis CN, Lowe N, Goldfarb MT, Baughman RD (1995) The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. J Am Acad Dermatol 33:44–52PubMedCrossRef
31.
go back to reference Dixon WG, Watson KD, Lunt M, Hyrich KL (2007) Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56:2905–2912PubMedCrossRef Dixon WG, Watson KD, Lunt M, Hyrich KL (2007) Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56:2905–2912PubMedCrossRef
32.
go back to reference Nishida K, Okada Y, Nawata M, Saito K, Tanaka Y (2008) Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody. Endocr J 55:213–216PubMedCrossRef Nishida K, Okada Y, Nawata M, Saito K, Tanaka Y (2008) Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody. Endocr J 55:213–216PubMedCrossRef
33.
go back to reference Komai N, Morita Y, Sakuta T, Kuwabara A, Kashihara N (2007) Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol 17:385–390PubMedCrossRef Komai N, Morita Y, Sakuta T, Kuwabara A, Kashihara N (2007) Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol 17:385–390PubMedCrossRef
34.
go back to reference Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F (2002) Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359:1173–1177PubMedCrossRef Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F (2002) Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359:1173–1177PubMedCrossRef
35.
go back to reference Van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE (2006) Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 8:R151PubMedCrossRef Van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE (2006) Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 8:R151PubMedCrossRef
36.
go back to reference Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS (2005) Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52:262–267PubMedCrossRef Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS (2005) Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52:262–267PubMedCrossRef
37.
go back to reference Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, Armstrong DJ (2009) More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 161(1):1–7PubMedCrossRef Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, Armstrong DJ (2009) More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 161(1):1–7PubMedCrossRef
Metadata
Title
Might psoriasis be a risk factor for obstructive sleep apnea syndrome?
Authors
Semsettin Karaca
Fatma Fidan
Faruk Erkan
Serkan Nural
Tulay Pinarcı
Ersin Gunay
Mehmet Unlu
Publication date
01-03-2013
Publisher
Springer-Verlag
Published in
Sleep and Breathing / Issue 1/2013
Print ISSN: 1520-9512
Electronic ISSN: 1522-1709
DOI
https://doi.org/10.1007/s11325-012-0686-2

Other articles of this Issue 1/2013

Sleep and Breathing 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine